These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24486022)

  • 1. The rate of overdiagnosis inextricably linked to prostate-specific antigen-based screening for prostate cancer can be quantified in several ways, but what is the practicable message?
    Roobol MJ; Schröder FH
    Eur Urol; 2014 Jun; 65(6):1056-7. PubMed ID: 24486022
    [No Abstract]   [Full Text] [Related]  

  • 2. Overdiagnosis and overtreatment of prostate cancer.
    Loeb S; Bjurlin MA; Nicholson J; Tammela TL; Penson DF; Carter HB; Carroll P; Etzioni R
    Eur Urol; 2014 Jun; 65(6):1046-55. PubMed ID: 24439788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen testing in france.
    Braillon A
    JAMA Intern Med; 2013 Nov; 173(21):2014. PubMed ID: 24276059
    [No Abstract]   [Full Text] [Related]  

  • 4. Why I will continue to screen prostate-specific antigen for myself and other appropriate men.
    Keller DL
    JAMA Intern Med; 2014 Jan; 174(1):164. PubMed ID: 24394929
    [No Abstract]   [Full Text] [Related]  

  • 5. Why I will continue to screen prostate-specific antigen for myself and other appropriate men--reply.
    Katz MH
    JAMA Intern Med; 2014 Jan; 174(1):164. PubMed ID: 24394931
    [No Abstract]   [Full Text] [Related]  

  • 6. Individualized prostate-specific antigen threshold values to avoid overdiagnosis of prostate cancer and reduce unnecessary biopsy in elderly men.
    Kanao K; Komori O; Nakashima J; Ohigashi T; Kikuchi E; Miyajima A; Nakagawa K; Eguchi S; Oya M
    Jpn J Clin Oncol; 2014 Sep; 44(9):852-9. PubMed ID: 25030213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen-based prostate cancer screening: Past and future.
    Alberts AR; Schoots IG; Roobol MJ
    Int J Urol; 2015 Jun; 22(6):524-32. PubMed ID: 25847604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.
    Morgan T; Palapattu G; Wei J
    Curr Urol Rep; 2015 Sep; 16(9):63. PubMed ID: 26169584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Belpomme D; Irigaray P
    J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
    [No Abstract]   [Full Text] [Related]  

  • 11. Patients Present with More Advanced Prostate Cancer since the USPSTF Screening Recommendations.
    Barry MJ; Nelson JB
    J Urol; 2015 Dec; 194(6):1534-6. PubMed ID: 26384450
    [No Abstract]   [Full Text] [Related]  

  • 12. Numbers needed to decide.
    Woloshin S; Schwartz LM
    J Natl Cancer Inst; 2009 Sep; 101(17):1163-5. PubMed ID: 19671771
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Prostate-specific antigen-based prostate cancer screening: Past and future.
    Birkeland S
    Int J Urol; 2016 Apr; 23(4):348. PubMed ID: 26839978
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial Comment to Prostate-specific antigen-based prostate cancer screening: Past and future.
    Sakamoto S
    Int J Urol; 2015 Jun; 22(6):532-3. PubMed ID: 25854711
    [No Abstract]   [Full Text] [Related]  

  • 15. Overdiagnosis and overtreatment of early detected prostate cancer.
    Bangma CH; Roemeling S; Schröder FH
    World J Urol; 2007 Mar; 25(1):3-9. PubMed ID: 17364211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers.
    Gandaglia G; Briganti A; Fossati N; Salonia A; Mottrie A; Catto J; Montorsi F
    Eur Urol; 2016 Oct; 70(4):547-548. PubMed ID: 26916048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.
    Shen X; Kumar P
    J Urol; 2016 May; 195(5):1397-1402. PubMed ID: 26656266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Related biomarkers in the diagnosis of prostate cancer].
    Xu YM; Liu HZ
    Zhonghua Nan Ke Xue; 2015 Oct; 21(10):937-40. PubMed ID: 26665686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.
    Braillon A; Dubois G
    J Natl Cancer Inst; 2012 May; 104(10):793; author reply 793-4. PubMed ID: 22491229
    [No Abstract]   [Full Text] [Related]  

  • 20. Cancer overdiagnosis and overtreatment.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):203-9. PubMed ID: 22472510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.